Fig. 3.

Combination therapy with a single dose of G12 with TDF and/or HBsAg-HBsAb immune-complex. AAV/HBV mouse model was established via injection of 10¹¹ AAV/HBV1.3. Mice were treated with 30 mg/kg TDF followed with 0.5 mg G12 infusion as indicated (a). Blood was collected two days after G12 injection and HBV DNA and HBsAg (b) were quantified. (c) AAV/HBV mouse model was established via injection of 2 × 10¹⁰ AAV/HBV1.3. 10 μg mYIC was intraperitoneally injected one hour before 0.5 mg G12 infusion and 30 mg/kg TDF was administered throughout the treatment as indicated. The serum was collected and the HBsAg level was quantified. (d) HBsAg levels at 12 and 19 days after G12 infusion are shown.